ArticleFrontiers in medicine2026
Interpretable machine learning to predict functional visual outcomes after the anti-VEGF loading phase for macular edema secondary to retinal vein occlusion: model development and temporal internal validation.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Functional visual outcomes in macular edema (ME) secondary to retinal vein occlusion (RVO) after the anti-vascular endothelial growth factor (VEGF) loading phase are highly variable. We aimed to develop and validate an interpretable prediction model integrating baseline clinical features and quantitative optical coherence tomography (OCT) biomarkers to identify RVO-ME patients at high risk of poor functional visual outcomes. Methods: This study retrospectively included 196 patients with RVO-ME. Adopting a rigorous temporal validation design, cases from 2021 to 2024 were assigned to the training set ( Results: Initially, LASSO regression identified five key predictors: baseline BCVA, age, RVO subtype, subretinal fluid (SRF) cross-sectional area, and length of disorganization of retinal inner layers (DRIL). The XGBoost model was selected as the best-performing model, showing strong performance in the test set (AUC, 0.898; 95% CI, 0.797-1.000; sensitivity, 0.917; specificity, 0.812) at the default probability threshold of 0.5. SHAP analysis identified baseline BCVA as the primary prognostic driver and suggested a non-linear relationship with prognosis, with a critical risk threshold at approximately 1.14 logMAR (95% CI: 1.07-1.20). Additionally, a heterogeneous, non-linear interaction pattern was observed between advanced age and severe baseline visual impairment. SHAP analysis identified SRF cross-sectional area and DRIL length as independent contributors to model predictions after accounting for other included features. Conclusion: XGBoost showed encouraging performance for predicting poor functional visual outcomes in patients with RVO-ME after the anti-VEGF loading phase and maintained high sensitivity in the independent temporal test cohort. Furthermore, SHAP analysis suggested a non-linear relationship between baseline BCVA and prognosis, with a breakpoint at approximately 1.14 logMAR, and highlighted the independent predictive value of quantitative DRIL and SRF in determining functional visual recovery. Overall, this study provides a proof-of-concept for interpretable prediction in RVO-ME and may help identify patients at higher risk of poor short-term functional outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.